2019 Fiscal Year Final Research Report

Evaluation of the role of gut-microbiota in NASH-associated HCC pathogenesis

Research Project

PDF

Project/Area Number	17K09434
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Gastroenterology
Research Institution	Yokohama City University
Principal Investigator	IMAJO KENTO 横浜市立大学, 附属病院, 助教 (30600192)
Co-Investigator(Kenkyū-buntansha)	斉藤聡横浜市立大学, 附属病院, 准教授 (00275041) 留野渉横浜市立大学, 医学研究科, 客員講師 (00644957) 本多靖横浜市立大学, 附属病院, 助教 (00784844) 米田正人横浜市立大学, 附属病院, 講師 (10423831) 小川祐二横浜市立大学, 医学部, 助教 (20644959) 中島淳横浜市立大学, 医学研究科, 教授 (30326037) 結束貴臣横浜市立大学, 附属病院, 助教 (30738620)
Project Period (FY)	2017-04-01 – 2020-03-31
Keywords	NASH由来肝細胞癌
Outline of Final Research Achievements	This study was to investigate the role of gut-microbiota and endotoxin (ET) in the pathogenesis of non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC). By fecal metagenomic analysis, the occupation rate of Faecalibacterium was lower in the feces of NASH-associated HCC model mice than in non-HCC mice. This result was similar to that of human HCC patients. Moreover, administration of Fecalibacterium to these HCC model mice resulted in a decrease in the number and size of HCC. Although increased intestinal permeability is considered as a mechanism of progress of NASH-derived HCC, improvement was observed by administration of Fecalibacterium.
Free Research Field	肝臓
Academic Significance and Societal Importance of the Research Achievements	NASH由来肝細胞癌は増加の一途を辿っている。本研究は腸内細菌がNASH由来肝細胞癌に関わることのみならず、腸内細菌の是正がNASH由来肝細胞癌を抑制できる可能性を示唆するものである。将来的に肝細胞癌の予防や治療において、腸内細菌や腸管透過性へのアプローチといったこれまでとは全く異なる選択肢へとつながる可能性がある。